| Literature DB >> 35566562 |
Omar Kherad1,2, Ezra Bottequin2, Dorsaf Steiner3, Axelle Alibert3,4, Rodolphe Eurin4, Hugo Bothorel5.
Abstract
BACKGROUND: The dissemination of recommendations on low-value care alone may not lead to physicians' behavioral changes. The aim of this study was to evaluate whether a multifaceted behavioral intervention among internal medicine residents could reduce low-value care in hospitalized patients.Entities:
Keywords: audit; data feedback; low-value care
Year: 2022 PMID: 35566562 PMCID: PMC9104072 DOI: 10.3390/jcm11092435
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Dynamic dashboard based on prescription data.
Prescription differences between the pre- and post-intervention periods.
| Pre-Intervention Period (1095 Patients) | Post-Intervention Period (1155 Patients) | ||||||
|---|---|---|---|---|---|---|---|
| N (%) | N(%) | ||||||
| Med | (IQR) | Med | (IQR) | ||||
|
| |||||||
| Age | 74.1 ± 15.5 | 77.5 | (67.0–85.0) | 73.3 ± 15.9 | 77.0 | (65.0–84.0) | 0.231 * |
| PCCL | 1.7 ± 1.6 | 2.0 | (0.0–3.0) | 1.7 ± 1.5 | 2.0 | (0.0–3.0) | 0.688 * |
| Length of stay (days) | 8.9 ± 8.7 | 6.7 | (3.3–11.2) | 8.8 ± 7.5 | 7.0 | (3.9–11.2) | 0.291 * |
| Age ≥ 65 y.o | 843 (77.0) | 835 (72.3) | 0.185 | ||||
| Male sex | 577 (52.7) | 584 (50.6) | 0.312 | ||||
|
| |||||||
| Patients with prescription | |||||||
| Benzodiazepine (≥65 y.o) | 156 (18.5) | 132 (15.8) | 0.143 | ||||
| Proton Pump Inhibitor | 186 (17.0) | 188 (16.3) | 0.652 | ||||
| Blood test | 902 (83.1) | 902 (78.1) |
| ||||
| Phys. prescription rate (%) ⟟ | |||||||
| Benzodiazepine (≥65 y.o) | 15.4 ± 17.6 | 14.6 | (0.0–22.6) | 11.7 ± 11.8 | 12.5 | (0.0–19.1) | 0.623 ⋄ |
| Proton Pump Inhibitor | 14.6 ± 14.3 | 13.5 | (13.5–0.0) | 16.4 ± 20.6 | 15.8 | (0.0–21.3) | 0.384 ⋄ |
| Blood test | 82.1 ± 22.2 | 83.6 | (81.2–100.0) | 78.4 ± 21.1 | 80.8 | (80.8–72.3) | |
| Blood tests per patient day ** | 0.54 ± 0.43 | 0.42 | (0.26–0.69) | 0.49 ± 0.60 | 0.37 | (0.20–0.57) | |
|
| |||||||
| Patients with prescription | |||||||
| Benzodiazepine (≥65 y.o) | 35 (4.2) | 14 (1.7) |
| ||||
| Proton Pump Inhibitor | 101 (9.2) | 108 (9.4) | 0.917 | ||||
| Phys. prescription rate (%) ⟟ | |||||||
| Benzodiazepine (≥65 y.o) | 4.0 ± 7.5 | 0.0 | (0.0–5.5) | 0.7 ± 2.1 | 0.0 | (0.0–0.0) | |
| Proton Pump Inhibitor | 8.6 ± 11.9 | 5.4 | (0.0–9.3) | 6.0 ± 6.2 | 5.7 | (0.0–9.3) | 0.394 ⋄ |
IQR, Interquartile range; PCCL, Patient clinical complexity level; y.o, year old; Med, Median; , Mean; SD, Standard deviation; Phys. Physician’s; Underlined values indicate significant p-values (<0.05); * p-value calculated using Wilcoxon rank sum tests; ** Among patients with the concerned prescription; ⋄ p-value obtained using Wilcoxon signed rank tests; ⟟ The mean physician’s prescription rates slightly differ from the proportions of patients with prescription since each physician did not treat the same number of patients over the period of interest.
Figure 2Evolution of the proportion of patients with a benzodiazepine prescription between the investigated periods. * Indicates a significant difference between the pre- and post-intervention prescription rate.
Figure 3Evolution of the proportion of patients with a blood test(s) prescription between the investigated periods. * Indicates a significant difference between the pre- and post-intervention prescription rate.
Comparison of safety endpoints between the pre- and post-intervention periods.
| Pre-Intervention (n = 1095 Patients) | Post-Intervention (n = 1155 Patients) | ||||||
|---|---|---|---|---|---|---|---|
| N (%) | N(%) | ||||||
| Med | (IQR) | Med | (IQR) | ||||
|
| |||||||
| Eligible hospitalisations | 656 | 685 | |||||
| Readmission rate (%) | 41 (6.3%) | 36 (5.3%) | 0.434 | ||||
| Readmission delay (days) | 11.9 ± 10.1 | 8.0 | (3.0–21.0) | 14.3 ± 8.6 | 14.0 | (6.5–22.3) | 0.160 * |
|
| |||||||
| Eligible hospitalisations | 992 | 1069 | |||||
| Death rate (%) | 24 (2.4%) | 22 (2.1%) | 0.579 | ||||
|
| |||||||
| Eligible hospitalisations | 1056 | 1133 | |||||
| Global complication score | 0.37 ± 1.17 | 0.00 | (0.00–0.00) | 0.30 ± 0.95 | 0.00 | (0.00–0.00) | 0.310 * |
All indicators were calculated using the SQLape software; IQR, Interquartile range; Pot. avoid., Potentially avoidable; Med, Median; , Mean; * p-value calculated using Wilcoxon rank sum tests.